CA3199559A1 - 5'-o-phenylacetyluridine and therapeutic use - Google Patents

5'-o-phenylacetyluridine and therapeutic use

Info

Publication number
CA3199559A1
CA3199559A1 CA3199559A CA3199559A CA3199559A1 CA 3199559 A1 CA3199559 A1 CA 3199559A1 CA 3199559 A CA3199559 A CA 3199559A CA 3199559 A CA3199559 A CA 3199559A CA 3199559 A1 CA3199559 A1 CA 3199559A1
Authority
CA
Canada
Prior art keywords
compound
uridine
condition
mammalian subject
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3199559A
Other languages
English (en)
French (fr)
Inventor
Rolando Alejandro GARCIA GARCIA
Joel A. Saydoff
David Michael Simpson
Reid Warren Von Borstel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Cinq LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3199559A1 publication Critical patent/CA3199559A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
CA3199559A 2020-12-01 2021-11-30 5'-o-phenylacetyluridine and therapeutic use Pending CA3199559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119764P 2020-12-01 2020-12-01
US63/119,764 2020-12-01
PCT/US2021/061053 WO2022119784A1 (en) 2020-12-01 2021-11-30 5'-o-phenylacetyluridine and therapeutic use

Publications (1)

Publication Number Publication Date
CA3199559A1 true CA3199559A1 (en) 2022-06-09

Family

ID=81854225

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3199559A Pending CA3199559A1 (en) 2020-12-01 2021-11-30 5'-o-phenylacetyluridine and therapeutic use

Country Status (16)

Country Link
US (1) US20230416292A1 (https=)
EP (2) EP4255563B1 (https=)
JP (1) JP2023551467A (https=)
KR (1) KR20230112118A (https=)
CN (1) CN116782912A (https=)
AU (1) AU2021391411A1 (https=)
BR (1) BR112023010517A2 (https=)
CA (1) CA3199559A1 (https=)
DK (1) DK4255563T3 (https=)
FI (1) FI4255563T3 (https=)
IL (1) IL303100A (https=)
LT (1) LT4255563T (https=)
MX (1) MX2023006343A (https=)
PL (1) PL4255563T3 (https=)
PT (1) PT4255563T (https=)
WO (1) WO2022119784A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4210709T (pt) 2020-09-14 2026-02-04 Pharma Cinq Llc 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿
TW202317144A (zh) * 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
JP2526414B2 (ja) 1994-05-20 1996-08-21 工業技術院長 制ガン剤エステル化合物及びその製造方法
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
EP1808177B1 (en) * 1999-02-23 2018-08-08 The Regents of The University of California Methods of treatment of mitochondrial disorders
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
PT2922576T (pt) * 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
PL3182980T3 (pl) * 2014-08-19 2021-04-19 Wellstat Therapeutics Corporation Leczenie chorób niedoboru glikozylacji
AU2019215105B2 (en) * 2018-02-01 2024-12-19 Pharma Cinq, Llc Compositions and devices for systemic delivery of uridine
WO2022089612A1 (zh) * 2020-10-30 2022-05-05 上海岸阔医药科技有限公司 尿苷衍生物在制备药物中的应用

Also Published As

Publication number Publication date
PL4255563T3 (pl) 2026-04-20
EP4255563B1 (en) 2025-12-31
WO2022119784A1 (en) 2022-06-09
JP2023551467A (ja) 2023-12-08
AU2021391411A1 (en) 2023-07-20
IL303100A (en) 2023-07-01
EP4711007A2 (en) 2026-03-18
PT4255563T (pt) 2026-03-24
MX2023006343A (es) 2023-06-12
CN116782912A (zh) 2023-09-19
BR112023010517A2 (pt) 2024-02-06
KR20230112118A (ko) 2023-07-26
EP4255563A1 (en) 2023-10-11
FI4255563T3 (fi) 2026-03-13
EP4711007A3 (en) 2026-04-01
AU2021391411A9 (en) 2024-07-18
EP4255563A4 (en) 2024-09-11
DK4255563T3 (da) 2026-03-16
LT4255563T (lt) 2026-04-10
US20230416292A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP2637534B2 (ja) アシルデオキシリボヌクレオシド誘導体およびその使用
EP0601322A2 (en) Adenosindeaminase inhibitor
SK63294A3 (en) Organic salts of n,n'-diacetylcystine
US11547681B2 (en) N-acylethanolamide derivatives and uses thereof
EP4255563B1 (en) 5'-O-PHENYLACETYLURIDINE AND THERAPEUTIC USE
CA2863339C (en) Forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
JP2650756B2 (ja) 皮膚および粘膜上皮の疾患の治療のための４‐キノリンカルボン酸誘導体
US8076346B2 (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
CN111635309B (zh) 一种新型解热镇痛药物及其制备方法和用途
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
EP0780125B1 (en) Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals
JP2001511447A (ja) Ｌ−カルニチンまたはアルカノイルｌ−カルニチンおよび長鎖アルカノイルを含む組成物
EP1781294B1 (en) Composition for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US5149688A (en) Methods, compounds, and compositions for immunosuppression
CS209856B2 (en) Method of making the new derivatives of the aminoacids
EP0617959A1 (en) Pharmaceutical for the treatment of skin disorders
US6743782B1 (en) Acyl deoxyribonucleoside derivatives and uses thereof
US4080442A (en) Disaccharide derivatives used in the treatment of hepatic diseases
JPH07118156A (ja) アデノシンデアミナーゼ阻害剤
US4124723A (en) Method for suppressing histamine release
CS221527B2 (en) Method of preparation of n-/1-methyl-2-pyrrolidinylmethyl/2,3-dimethoxy-5-methylsulphamoylbenzamide
JPH01199961A (ja) タウリン誘導体、その製法及びこれを含有する薬剤組成物
CS209860B2 (cs) Způsob výroby nových derivátů aminokyselin
HK1108313B (en) Composition for improved bioavailability and enhanced brain delivery of 5, 5-diphenyl barbituric acid
JPS63258421A (ja) 糖ラクタムを含有する抗炎症剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241114

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250530

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251126